Selective inhibition of IDO has been increasingly shown to prevent its immunosuppressive effect on antitumor T cell activation, which is currently being tested in preclinical models of ccRCC [46, 47]. This evidence concerns the gene IDO1 and nonpapillary renal cell carcinoma.